A. Waldeck

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

S. Srinivas, N. Joshi, M. Botteman, 2020, BMC Urology.

Insights into Treatment Patterns in the Routine Care of Patients Diagnosed with Metastatic Castration-Resistant Prostate Cancer in Germany After the Introduction of New Therapies

P. Goebell, A. Waldeck, N. Justo, 2020 .

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment

S. Srinivas, N. Joshi, M. Botteman, 2020, Cancer medicine.

Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

S. Halabi, R. Ayyagari, N. Shore, 2021, The Journal of urology.

The Hospitalization-Related Costs of Adverse Events for Novel Androgen Receptor Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: An Indirect Comparison

R. Ayyagari, N. Shore, A. Waldeck, 2022, Advances in Therapy.

Frequency, management, and resource use of adverse events (AEs) in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients receiving apalutamide or enzalutamide: A real-world study.

S. Corman, A. Hussain, S. Appukkuttan, 2021 .

The ideology of ISIS - a motivation for Europeans to become foreign fighters?

Annika Waldeck, A. Waldeck, 2015 .

Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients

A. Norden, M. Botteman, A. Aly, 2017, Journal of medical economics.

The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.

Richard E. White, Ben A van Hout, B. van Hout, 2017, Journal of managed care & specialty pharmacy.